- Home
- TALK vs ORKA Comparison
TALK vs ORKA Comparison
Compare TALK & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALK
- ORKA
- Stock Information
- Founded
- TALK 2012
- ORKA 2004
- Country
- TALK United States
- ORKA United States
- Employees
- TALK N/A
- ORKA N/A
- Industry
- TALK Medical/Nursing Services
- ORKA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TALK Health Care
- ORKA Health Care
- Exchange
- TALK Nasdaq
- ORKA Nasdaq
- Market Cap
- TALK 434.6M
- ORKA 393.1M
- IPO Year
- TALK N/A
- ORKA N/A
- Fundamental
- Price
- TALK $3.02
- ORKA $9.54
- Analyst Decision
- TALK Buy
- ORKA Strong Buy
- Analyst Count
- TALK 6
- ORKA 7
- Target Price
- TALK $4.50
- ORKA $39.67
- AVG Volume (30 Days)
- TALK 1.5M
- ORKA 189.2K
- Earning Date
- TALK 05-06-2025
- ORKA 05-19-2025
- Dividend Yield
- TALK N/A
- ORKA N/A
- EPS Growth
- TALK N/A
- ORKA N/A
- EPS
- TALK 0.02
- ORKA N/A
- Revenue
- TALK $194,359,000.00
- ORKA N/A
- Revenue This Year
- TALK $23.21
- ORKA N/A
- Revenue Next Year
- TALK $20.87
- ORKA N/A
- P/E Ratio
- TALK $173.65
- ORKA N/A
- Revenue Growth
- TALK 19.88
- ORKA N/A
- 52 Week Low
- TALK $1.60
- ORKA $5.49
- 52 Week High
- TALK $4.36
- ORKA $53.88
- Technical
- Relative Strength Index (RSI)
- TALK 52.96
- ORKA N/A
- Support Level
- TALK $2.75
- ORKA N/A
- Resistance Level
- TALK $3.30
- ORKA N/A
- Average True Range (ATR)
- TALK 0.19
- ORKA 0.00
- MACD
- TALK 0.00
- ORKA 0.00
- Stochastic Oscillator
- TALK 58.82
- ORKA 0.00
About TALK Talkspace Inc.
Talkspace Inc is a behavioral healthcare company offering access to licensed therapists, psychologists, and psychiatrists through its technology platform. It serves clients including health plans, enterprises, and individual subscribers. Therapists address various mental health conditions, while psychiatrists cater to a higher acuity demographic. Revenue stems from payor and direct-to-enterprise clients, with contracts lasting one to three years. The majority of the Company's operations and revenues are based in the United States.
About ORKA Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.